Evidence map›Paper›PMID 24828440›Full record

ArticlePloS one2014

Broad T-cell receptor repertoire in T-lymphocytes derived from human induced pluripotent stem cells.

Chia-Wei Chang, Yi-Shin Lai, Lawrence S Lamb, Tim M Townes

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed.

  1. Efficient Generation of Functional TCRαβbioRxiv : the preprint server for biology · 2026
    Article
  2. Article
  3. Review
  4. Review
  5. Adoptive Cell Therapy from the Dish: Potentiating Induced Pluripotent Stem Cells.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2025
    Review
  6. Generation ofHeliyon · 2024
    Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Producing proT cells to promote immunotherapies.International immunology · 2018
    Review
  17. Review
  18. Review
  19. Review
  20. T Cell Genesis: In Vitro Veritas Est?Trends in immunology · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Chia-Wei ChangDepartment of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Schools of Medicine and Dentistry, Birmingham, Alabama, United States of America; UAB Stem Cell Institute, University of Alabama at Birmingham, Schools of Medicine and Dentistry, Birmingham, Alabama, United States of America.
Yi-Shin LaiDepartment of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Schools of Medicine and Dentistry, Birmingham, Alabama, United States of America; UAB Stem Cell Institute, University of Alabama at Birmingham, Schools of Medicine and Dentistry, Birmingham, Alabama, United States of America.
Lawrence S LambDepartment of Medicine, University of Alabama at Birmingham, Schools of Medicine and Dentistry, Birmingham, Alabama, United States of America; Cell Therapy Lab, University of Alabama at Birmingham, Schools of Medicine and Dentistry, Birmingham, Alabama, United States of America.
Tim M TownesDepartment of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Schools of Medicine and Dentistry, Birmingham, Alabama, United States of America; UAB Stem Cell Institute, University of Alabama at Birmingham, Schools of Medicine and Dentistry, Birmingham, Alabama, United States of America.

Funding

Mouse Model of Sickle Cell Disease and Genetic TherapiesR01HL057619 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI TOWNES, TIM M. · 1996 to 2014
$5.3M
NHLBI NIH HHS R01 HL057619NHLBI NIH HHS R01HL057619
6 · The paper itself

Abstract

Human induced pluripotent stem cells (hiPSCs) have enormous potential for the treatment of inherited and acquired disorders. Recently, antigen-specific T lymphocytes derived from hiPSCs have been reported. However, T lymphocyte populations with broad T cell receptor (TCR) diversity have not been generated. We report that hiPSCs derived from skin biopsy are capable of producing T lymphocyte populations with a broad TCR repertoire. In vitro T cell differentiation follows a similar developmental program as observed in vivo, indicated by sequential expression of CD7, intracellular CD3 and surface CD3. The γδ TCR locus is rearranged first and is followed by rearrangement of the αβ locus. Both γδ and αβ T cells display a diverse TCR repertoire. Upon activation, the cells express CD25, CD69, cytokines (TNF-α, IFN-γ, IL-2) and cytolytic proteins (Perforin and Granzyme-B). These results suggest that most, if not all, mechanisms required to generate functional T cells with a broad TCR repertoire are intact in our in vitro differentiation protocol. These data provide a foundation for production of patient-specific T cells for the treatment of acquired or inherited immune disorders and for cancer immunotherapy.

Indexed as

Cell DifferentiationCell LineGranzymesHumansInduced Pluripotent Stem CellsInterferon-gammaInterleukin-2Lymphocyte ActivationPerforinReceptors, Antigen, T-Cell, gamma-deltaT-LymphocytesTumor Necrosis Factor-alphaGranzymesInterferon-gammaInterleukin-2PerforinReceptors, Antigen, T-Cell, gamma-deltaTumor Necrosis Factor-alpha

Identifiers

PMID24828440
PMCPMC4020825

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.